- Home
- RMBI vs CABA Comparison
RMBI vs CABA Comparison
Compare RMBI & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMBI
- CABA
- Stock Information
- Founded
- RMBI 1887
- CABA 2017
- Country
- RMBI United States
- CABA United States
- Employees
- RMBI N/A
- CABA N/A
- Industry
- RMBI Major Banks
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RMBI Finance
- CABA Health Care
- Exchange
- RMBI Nasdaq
- CABA Nasdaq
- Market Cap
- RMBI 128.3M
- CABA 118.8M
- IPO Year
- RMBI 2019
- CABA 2019
- Fundamental
- Price
- RMBI $12.75
- CABA $1.17
- Analyst Decision
- RMBI
- CABA Strong Buy
- Analyst Count
- RMBI 0
- CABA 10
- Target Price
- RMBI N/A
- CABA $24.80
- AVG Volume (30 Days)
- RMBI 28.9K
- CABA 802.2K
- Earning Date
- RMBI 04-24-2025
- CABA 05-14-2025
- Dividend Yield
- RMBI 4.69%
- CABA N/A
- EPS Growth
- RMBI 1.10
- CABA N/A
- EPS
- RMBI 0.92
- CABA N/A
- Revenue
- RMBI $42,915,048.00
- CABA N/A
- Revenue This Year
- RMBI N/A
- CABA N/A
- Revenue Next Year
- RMBI N/A
- CABA N/A
- P/E Ratio
- RMBI $13.91
- CABA N/A
- Revenue Growth
- RMBI 2.81
- CABA N/A
- 52 Week Low
- RMBI $10.15
- CABA $1.16
- 52 Week High
- RMBI $15.15
- CABA $19.04
- Technical
- Relative Strength Index (RSI)
- RMBI 48.63
- CABA 24.03
- Support Level
- RMBI $12.60
- CABA $1.45
- Resistance Level
- RMBI $13.40
- CABA $1.85
- Average True Range (ATR)
- RMBI 0.38
- CABA 0.14
- MACD
- RMBI 0.08
- CABA -0.03
- Stochastic Oscillator
- RMBI 52.90
- CABA 1.78
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.